Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000 shares of common stock of Aimmune Therapeutics, Inc. BofA…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now